With a com­pet­i­tive Bill Si­bold tak­ing the helm at Sanofi Gen­zyme, long­time ex­ec David Meek­er makes an ex­it

When Sanofi stepped in close to six years ago and bought out Gen­zyme for $20 bil­lion, the phar­ma gi­ant pro­mot­ed David Meek­er to take the helm of the cru­cial op­er­a­tion in Boston. To­day, Meek­er says he’s leav­ing af­ter 23 years at the com­pa­ny, and he’ll be re­placed by the MS fran­chise chief Bill Si­bold.

It was Meek­er and Si­bold who man­aged the suc­cess­ful roll­out of Auba­gio and Lem­tra­da — which had to bat­tle back from a crush­ing CRL. The two MS drugs that now make up a sig­nif­i­cant part of Sanofi’s over­all rev­enue. And it’s Si­bold who was in charge of prepar­ing the launch of the new­ly ap­proved eczema drug Dupix­ent (dupilum­ab) — tapped as a like­ly megablock­buster — as well as sar­ilum­ab, which was de­layed at the FDA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.